Transferred from: Medicilon

Recently, Fujian Shengdi Pharmaceutical Co., Ltd. (hereinafter referred to as "Shengdi Pharmaceutical"), a subsidiary of Jiangsu Hengrui Pharmaceutical Co., Ltd. (hereinafter referred to as "Hengrui Pharmaceutical"), independently developed a small interfering nucleic acid (siRNA) class I innovative drug HRS-9563 injection, which is intended to be used for the treatment of hypertension.

Shanghai Medicilon Biopharmaceutical Co., Ltd. (hereinafter referred to as "Medicilon"), as a strategic partner of Hengrui Pharmaceutical, has provided preclinical pharmacokinetic studies and safety evaluations under GLP for the research and development of HRS-9563 injection. The approval of HRS-9563 injection is another important achievement of the in-depth cooperation between Hengrui Pharmaceutical and Medicilon!

siRNA drug HRS-9563 injection

Bringing a new dawn to the field of hypertension treatment

Hypertension has long been a major global public health challenge due to its high incidence and high risk of chronic cardiovascular disease. In its treatment, the convenience of medication for patients is low, and the effectiveness of existing drugs in some patients is poor. Hengrui Pharmaceutical's HRS-9563 injection effectively inhibits the expression of key proteins that cause elevated blood pressure by precisely targeting specific gene sequences, which is expected to overcome the above shortcomings of current therapeutic drugs.

In recent years, nucleic acid drugs have become a research hotspot in the field of biomedicine. The Nobel Prize in Physiology or Medicine recognizes scientists in the field of nucleic acid drugs, and it is a full affirmation of their value potential. The successful approval of HRS-9563 injection is a vivid example of this trend, and also fully demonstrates the strength and potential of Hengrui Pharmaceutical in innovative drug research and development.

　　MEDICILON

Medicilon nucleic acid drug R&D service platform

One-stop help for preclinical research and development of nucleic acid drugs

Innovation is not only the core driving force for the successful transformation of Hengrui Pharmaceutical, opening up a new channel for its growth, but also injecting inexhaustible impetus into Medicilon's deep cultivation in the field of biomedicine. At the forefront of nucleic acid drugs, Medicilon has built a one-stop preclinical R&D service platform for nucleic acid drugs. The platform integrates the integrated service chain of drug discovery, production and preparation, and preclinical research, and can provide nucleic acid drug discovery, screening, and preclinical research services, accurately meeting the industry's urgent needs for cutting-edge innovative nucleic acid drugs.

At present, Medicilon has completed a number of nucleic acid drug synthesis, biological in vitro screening, process scale-up, preclinical efficacy & pharmacokinetics and safety evaluation projects, and established a complete analysis method system for small nucleic acids. These rich practical experiences have established a good reputation for Medicilon in the field of nucleic acid drug research and development, and also laid a solid foundation for its in-depth cooperation with partners such as Hengrui Pharmaceutical.

Medicilon congratulates Hengrui Pharmaceutical HRS-9563 injection on its approval for clinical trials, and looks forward to achieving more remarkable results in clinical trials and bringing good news to hypertensive patients as soon as possible. In the future, Medicilon will continue to deepen its exploration and research in the field of nucleic acid drugs, and provide all-round preclinical research support for innovative pharmaceutical companies. I believe that with the empowerment of Medicilon, more innovative drugs like HRS-9563 injection will be put into clinical practice!

About Hengrui Pharmaceutical

Founded in 1970 and listed on the Shanghai Stock Exchange in 2000, Hengrui Pharmaceutical is an innovative international pharmaceutical company focusing on R&D, production and promotion of high-quality drugs, focusing on the research and development of new drugs in the fields of anti-tumor, metabolic diseases, autoimmune diseases, respiratory diseases, and nervous system diseases, and is one of the leading pharmaceutical companies with the most innovative capabilities in China.

For more than 50 years, Hengrui Pharmaceutical has always adhered to the original intention of serving patients, striving to protect the healthy life and quality of life of patients, and overcoming difficulties to promote the high-quality development of the pharmaceutical industry. In the TOP50 list of global pharmaceutical companies published by United States Pharmaceutical Manager Magazine, Hengrui Pharmaceutical has been on the list for 5 consecutive years; In the list of the world's top 25 pipeline pharmaceutical companies released by Citeline, an internationally renowned consulting agency, Hengrui Pharmaceutical has been on the list for three consecutive years, and its ranking will jump to 8th in 2024, setting a new high for Chinese pharmaceutical companies; In the "2023 Hurun Global 500" released by the Hurun Research Institute, Hengrui Pharmaceutical ranked 366th; In the "Best Industrial Enterprise of China's Pharmaceutical R&D Product Line" released by China Pharmaceutical Industry Information Center over the years, Hengrui Pharmaceutical has topped the list 11 times.

Preview of the live stream

Medicilon (stock code: 688202.HK) Founded in 2004 and headquartered in Shanghai, SH is committed to providing a full range of preclinical new drug research services for global pharmaceutical companies, research institutions and researchers. Medicilon's one-stop comprehensive service helps customers accelerate the process of new drug development with strong project management and more efficient and cost-effective R&D services, covering the whole process of pharmaceutical preclinical new drug research, including drug discovery, pharmaceutical research and preclinical research. By the end of June 2024, Medicilon has provided drug R&D services to more than 2,000 customers around the world, and has participated in the research and development of 490 IND approved clinical trials of new drugs and generic drugs, growing together with high-quality customers at home and abroad. Medicilon will continue to be based on a global vision, focus on China's innovation, and contribute to human health!

(Redirected from: Medicilon).